70 healthy adults will participate in a clinical trial for the malaria vaccine coded PfCP2.9 produced in China. The trial will last for eight months.
According to Chinese health authorities, if the trial on volunteers at Changhai Hospital in Shanghai is successful, complete clinical trials will be conducted involving a larger group of adults and children in areas with high malaria prevalence.
The program is sponsored by the international organization PATH and the Malaria Vaccine Initiative, in collaboration with Shanghai Wanxing Biological Pharmacy Co., Ltd and scientists from the Second Military Medical University in Shanghai to research and develop this vaccine. The program has received $2 million in funding along with technical assistance and data analysis from these organizations. PfCP2.9 is one of 20 malaria vaccines worldwide that have received funding from PATH to conduct clinical trials.
In China, the majority of malaria cases are reported in the southern provinces of Yunnan and Hainan.
DUC TRUONG
